Skip to main content

Advertisement

SpringerLink
Log in

Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: Epigenetic silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation and chromatin deacetylation provides interesting targets for chemotherapeutic intervention by inhibitors of these events. 5-Aza-2′-deoxycytidine (decitabine, 5AZA-CdR) is a potent demethylating agent, which can reactivate TSGs silenced by aberrant DNA methylation. LAQ824 (LAQ) is a novel inhibitor of histone deacetylase (HDAC) that shows antineoplastic activity and can activate genes that produce cell cycle arrest. Both 5AZA-CdR and LAQ as single agents are currently under clinical investigation in patients with cancer. Previous reports indicate that the “cross-talk” between inhibitors of DNA methylation and HDAC can result in a synergistic activation of silent TSGs. These observations suggest that combination of these inhibitors may be an effective form of epigenetic therapy for breast cancer. The objective of our study was to determine if the combination of 5AZA-CdR and LAQ would show additive or synergistic antineoplastic activity on human MDA-MB-231 and MCF-7 breast carcinoma cells. The antineoplastic activity of these agents was evaluated by clonogenic assay and inhibition of DNA synthesis. Results: The combination produced greater antineoplastic activity for the MDA-MB-231 tumor cells than either agent alone. For the MCF-7 tumor cells, there were signs of antagonism between 5AZA-CdR and LAQ when administered simultaneously. When a sequential schedule (first 5AZA-CdR followed by LAQ) was used, there were no signs of antagonism of the antineoplastic action for the MCF-7 tumor cells. The mechanism of this interaction is probably due to the reduction of progression of MCF-7 tumor cells into S phase by LAQ. This would interfere with the antineoplastic action of 5AZA-CdR, since it is an S phase specific agent. Conclusions: These studies demonstrated the importance of the schedule of administration of 5AZA-CdR and LAQ and may have application for future clinical trials on the treatment of breast cancer with these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Archer SY, Hoddin RA (1999) Histone acetylation and cancer. Curr Opin Genet Dev 9:171–174

    Article  PubMed  CAS  Google Scholar 

  2. Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, Remiszewski S (2004) Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64:689–695

    Article  PubMed  CAS  Google Scholar 

  3. Baylin SB (2002) Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 12:331–337

    Article  PubMed  CAS  Google Scholar 

  4. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, Baylin SB (2003) Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63:7089–7093

    PubMed  CAS  Google Scholar 

  5. Bovenzi V, Momparler RL (2001) Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 48(1):71–76

    Article  PubMed  CAS  Google Scholar 

  6. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103–107

    Article  PubMed  CAS  Google Scholar 

  7. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495–528

    Article  PubMed  CAS  Google Scholar 

  8. Garcia-Manero G, Issa J-P (2005) Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Invest 23:635–642

    Article  PubMed  CAS  Google Scholar 

  9. Gilbert J, Gore SD, Herman JG, Carducci MA (2004) The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10:4589–4596

    Article  PubMed  CAS  Google Scholar 

  10. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635–1640

    Article  PubMed  CAS  Google Scholar 

  11. Jones PA, Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21:163–167

    Article  PubMed  CAS  Google Scholar 

  12. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210–1216

    Article  PubMed  CAS  Google Scholar 

  13. Maslak P, Channel S, Camacho LH, Soignet S, Pandolfi PP, Guernah I, Warrell R, Nimer S (2006) Pilot study of combination of transcriptional modulation therapy with sodium phenylbutyrate and 5-azacitidine in patients with acute myeloid leukemia ore myelodysplastic syndrome. Leukemia 20:212–217

    Article  PubMed  CAS  Google Scholar 

  14. Momparler RL, Samson J, Momparler LF, Rivard GE (1984) Cell cycle effects and cellular pharmacology of 5-AZA-2′-deoxycytidine. Cancer Chemother Pharmacol 13:191–194

    Article  PubMed  CAS  Google Scholar 

  15. Momparler RL, Bovenzi V (2000) DNA methylation and cancer. J Cell Physiol 183:145–154

    Article  PubMed  CAS  Google Scholar 

  16. Momparler RL, Ayoub J. (2001) Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 34:S111–S115

    Article  PubMed  Google Scholar 

  17. Momparler RL (2005) Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin Hematol 42(3 Suppl 2):S9–S16

    Article  PubMed  CAS  Google Scholar 

  18. Primeau M, Gagnon J, Momparler RL (2003) Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 103:177–184

    Article  PubMed  CAS  Google Scholar 

  19. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P (2003) N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 46:1609–1621

    Article  CAS  Google Scholar 

  20. Richel DJ, Colly LP, Kluin-Nelemans JC, Willemze R (1991) The antileukaemic activity of 5-Aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer 64:144–148

    PubMed  CAS  Google Scholar 

  21. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin K, Momparler LF (1981) Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 5:453–462

    Article  PubMed  CAS  Google Scholar 

  22. Rudek MA, Zhao M, He P, Hartke C, Gilbert J, Gore SD, Carducci MA, Baker SD (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with solid tumors or haematological malignancies. J Clin Oncol 23:3906–3911.

    Article  PubMed  CAS  Google Scholar 

  23. Sanchez-Gonzales B, Yang H, Cuadros M, Santos-Malave C, Hoshino K, Kantarjian H, Issa JP, Garcia-Manero G (2005) In vivo molecular implications of the combination of the hypomethylating agent 5-aza-2′-deoxycytidine and the histone deacetylase inhibitor valproic acid in patients with leukemia: results of a phase I/II study. Proceeding AACR 46:937 (#3979)

    Google Scholar 

  24. Schrump DS, Nguyen DM, Kunst TE, Hancox A, Figg WD, Steinberg SM, Pishchik V, Becerra Y (2002) Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lung or pleura. Clin Lung Cancer 4(3):186–192

    Article  PubMed  CAS  Google Scholar 

  25. Wolffe AP (1996) Histone deacetylase: a regulator of transcription. Science 272:371–372

    Article  PubMed  CAS  Google Scholar 

  26. http://www.clinicaltrials.gov/ct/show/NCT00101179 MS-275 and Azacytidine in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia or acute myeloid leukemia. NCT00101179

Download references

Acknowledgement

This study was supported by a grant from the Canadian Cancer Society (RLM #014193). AH is supported by a studentship from the Fonds de la recherche en santé du Québec.

Author information

Authors and Affiliations

  1. Département de pharmacologie, Centre de recherche pédiatrique, Service d’hématologie-oncologie, Hôpital Sainte-Justine, Université de Montréal, 3175 Côte Sainte-Catherine, H3T 1C5, Montréal, QC, Canada

    Annie Hurtubise & Richard L. Momparler

Authors
  1. Annie Hurtubise
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard L. Momparler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard L. Momparler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hurtubise, A., Momparler, R.L. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2′-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol 58, 618–625 (2006). https://doi.org/10.1007/s00280-006-0225-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0225-6

Keywords

Search

Navigation